Foghorn Therapeutics Inc reports a Return on Equity (ROE) of 98.58%.

What is FHTX's dividend yield?

Foghorn Therapeutics Inc offers a dividend yield of 0.00%.

What is FHTX's Quality Score?

Our AI rates FHTX's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy FHTX?

Our AI Timing Score for FHTX is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does FHTX belong to?

Foghorn Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Foghorn Therapeutics Inc (FHTX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

FHTX AI Analysis Summary

Our AI summary for FHTX: Foghorn Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 98.58%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

FHTX

Foghorn Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 78

USD 4.86

0.25 (5.42%) Day Change

Watchlist Portfolio Compare Chart

-0.02

D/E

98.6%

ROE

-33.9%

ROA

0.00%

Div Yield

FOGHORN THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 4.86 Price 0.25 (5.42%) Day Change	NEWS SCORE: 78

FHTX, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	78
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	4.86
PBV / Sector	-3.54 / 44,022.72
Earning Per Share	-1.35

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	1.44 M GREAT
Average 1W Daily Value	0.85 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-266.88 / 98.24
NPM Average (%) / Sector	-348.97 / -1,697.63
NPM Change Average (%) / Sector	-10.59 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-33.90 / 185,260.96
ROA Average (%) / Sector	-32.64 / 36,684.70
ROA Change Average (%) / Sector	7.49 / 422,221.66
ROE (%) / Sector	98.58 / 243,762.23 GREAT
ROE Average (%) / Sector	-19,344.78 / 48,758.47
ROE Change Average (%) / Sector	-17.74 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:12
Symbol	FHTX
Name	FOGHORN THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	58.71 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	270.67 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 99 Coolidge Avenue, Watertown, MA, United States, 02472

Phone: 617 586 3100

Website: https://foghorntx.com

Employees: 106

Sector: Healthcare >> Biotechnology

Description: Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.